• Explore /
  • Poster
  • / Strategic treatment pause of first-line immune checkpoint inhibitor + VEGFR-tyrosine kinase inhibitor in patients with good or intermediate risk metastatic renal cell carcinoma (mRCC) in response at 1 year of treatment (SPICI-GETUG R05): A non-inferiority randomized clinical trial.

Strategic treatment pause of first-line immune checkpoint inhibitor + VEGFR-tyrosine kinase inhibitor in patients with good or intermediate risk metastatic renal cell carcinoma (mRCC) in response at 1 year of treatment (SPICI-GETUG R05): A non-inferiority randomized clinical trial.

Abstract Poster

Authors

null

Marine Gross-Goupil

Centre Hospitalo-Universitaire Saint André, Bordeaux, France

Marine Gross-Goupil , Felix Lefort , Mathieu Larroquette , Julien Asselineau , Eric Frison , Laurence Albiges , Alain Ravaud

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05219318

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS487)

DOI

10.1200/JCO.2024.42.4_suppl.TPS487

Abstract #

TPS487

Poster Bd #

M8

Abstract Disclosures

Similar Posters

First Author: Junjie Zhao

First Author: Can Aydogdu

First Author: Anwaar Saeed

First Author: Daniel Yick Chin Heng